trial · primary record
CLN-049
Relapsed/Refractory Acute Myeloid Leukemia (AML)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 275 |
| Primary completion | 2029-12-30 |
| Primary endpoint | Number of treatment emergent events (TEAEs) |
| Registry ID | NCT05143996 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:07.595Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05143996
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cln-049 · compound